Skip to main content

Advertisement

SpringerLink
Log in

Drug resistance in chemotherapy for breast cancer

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Recent developments with chemotherapy for breast cancer have improved patient survival. However, there continue to be nonresponders to conventional anticancer agents. Multidrug resistance (MDR) is caused by the expression of P-glycoprotein (P-gp) on the cell membrane. The expression of P-gp is encoded by MDR1 mRNA in tumors and is associated with clinical drug resistance. Since P-gp appears to be involved in both acquired and congenital MDR in human cancers, P-gp could be an important target for improving the efficacy of chemotherapy. Recently, we have focused on a therapeutic approach to reduce drug resistance in chemotherapy for breast cancer. Dofequidar fumarate (Dof) is a novel, orally active quinoline derivative that reverses multidrug resistance. In preclinical studies, the inhibition of doxorubicin-resistant cancer cell lines was observed in the presence of Dof + doxorubicin. We conducted clinical trials including Dof + cyclophosphamide (C), doxorubicin (A), and fluorouracil therapy (F) for patients with advanced or recurrent breast cancer. We compared the efficacy and tolerability of Dof + CAF with CAF alone. In this randomized, placebo-controlled trial, all patients were treated with six cycles of CAF therapy. Patients received Dof (900 mg p.o.) 30 min before doxorubicin. The primary endpoint was overall response rate (partial or complete response). In total, 221 patients were evaluable. The overall response rate was 42.6% for CAF alone versus 53.1% for Dof + CAF. Although the response rate improved by more than 10% with the combination of Dof + CAF, it was not statistically significant. Initially, we were expecting more than 20% improvement in the overall response rate. However, Dof significantly improved progression-free survival in patients who were premenopausal (P=0.046), who had received no prior therapy (P<0.01), or patients with advanced (stage IV) primary tumors (P=0.017). In addition, treatment with Dof did not affect the plasma concentration of doxorubicin in patients. These clinical studies indicate that Dof was well tolerated and displayed promising efficacy in patients who had not received prior therapy. The antiestrogens, tamoxifen, and toremifene, may moderate P-gp-related drug resistance in vitro. Toremifene demonstrated a synergistic effect in combination with paclitaxel on various human breast cancer cell lines. Furthermore, a synergistic effect was observed on a multidrug-resistant cell line. This synergistic effect was more potent when paclitaxel was combined with toremifene than with tamoxifen. Clinical benefits in some patients with recurrent breast cancer were reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Baba M (1995) Expression of MDR gene and drug resistance. BIO Clin 10:76

    Google Scholar 

  2. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D, in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184

    PubMed  CAS  Google Scholar 

  3. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410

    Article  PubMed  CAS  Google Scholar 

  4. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P (1996) Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292–300

    Article  PubMed  CAS  Google Scholar 

  5. Chevillard S, Lebeau J, Pouillart P, de Thoma C, Beldjord C, Asselain B, Klijainenko J, Fourquet A, Magdelenat H, Vielh P (1997) Biological clinical significance of concurrent p53 gene alterations, MDR1 gene expression, S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471–2478

    PubMed  CAS  Google Scholar 

  6. Childs S, Yeh RL, Hui D, Ling V (1998) Taxol resistance mediated by transfection of liver-specific sister gene of P-glycoprotein. Cancer Res 58:4160–4167

    PubMed  CAS  Google Scholar 

  7. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deely RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910

    PubMed  CAS  Google Scholar 

  8. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166

    Article  PubMed  CAS  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942

    Google Scholar 

  10. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL, Levy L (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005–1018

    Google Scholar 

  11. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682

    Article  PubMed  CAS  Google Scholar 

  12. Gianni L, Capri G, Munzone E, Straneo M (1994) Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21(5 Suppl 8):29–33

    PubMed  CAS  Google Scholar 

  13. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983

    Article  PubMed  CAS  Google Scholar 

  14. Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group Study. Cancer 38:13–20

    Google Scholar 

  15. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK (2001) Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824–842

    Article  PubMed  CAS  Google Scholar 

  16. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162

    Article  PubMed  CAS  Google Scholar 

  17. Keen JC, Miller EP, Bellamy C, Dixon JM, Miller WR (1994) P-glycoprotein and resistance to tamoxifen. Lancet 343:1047–1048

    Article  PubMed  CAS  Google Scholar 

  18. Kuroiwa S, Maruyama S, Okada M, Abe F (1998) The in vitro combination-effect of toremifene with CAF on growth of various human mammary carcinomas. Jpn J Cancer Chemother 25:1581–1589

    CAS  Google Scholar 

  19. Leonessa F, Clark R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73

    Article  PubMed  CAS  Google Scholar 

  20. Loffler TM (1998) Is there a place for “dose-dense” weekly schedules of the taxoids? Semin Oncol 12(5 Suppl 12):32–34

    Google Scholar 

  21. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N, NSABP Operations and Biostatistical Center, Pittsburgh, PA (2003) Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 (abstract 12). Proc Am Soc Clin Oncol 22:4

    Google Scholar 

  22. Maruyama S, Kuroiwa S, Saimoto A, Nishikawa K (2003) Combined effects of toremifene and paclitaxel on human breast cancer cell lines (in Japanese). Jpn J Cancer Chemother 30:669–675

    CAS  Google Scholar 

  23. Morgan GW (2005) Reduction in mortality from breast cancer: reasons for improved survival are more complex than suggested. Br Med J 30:1025

    Article  Google Scholar 

  24. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A, Breast Cancer Intl Research Group, Los Angeles, CA (2002) Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study (abstract 141). Proc Am Soc Clin Oncol 21:36a

  25. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618

    Article  PubMed  CAS  Google Scholar 

  26. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A (1997) Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double blind—The “Nordic” phase III study. Br J Cancer 76:270–277

    PubMed  CAS  Google Scholar 

  27. Saeki T (2004) Dofequidar fumarate (MS 209) in combination with CAF compared with CAF alone for patients with advanced or recurrent breast cancer. Proc ESMO, Vienna, Abstract 107

  28. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL (1987) Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262:7884–7888

    PubMed  CAS  Google Scholar 

  29. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T (1995) Reversal of multidrug resistance by a novel quinoline derivative, MS 209. Cancer Chem Pharm 35:271–277

    Article  CAS  Google Scholar 

  30. Scala S, Saeki T, Lynch A, Salomon D, Meriono MJ, Bates SE (1995) Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. Diagn Mol Pathol 4:136–142

    Article  PubMed  CAS  Google Scholar 

  31. Sonnichsen DS, Relling MV (1998) Paclitaxel and docetaxel. In: Grochow LB, Ames MM (eds) A clinician’s guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams & Wilkins, Baltimore, pp 375–394

    Google Scholar 

  32. Suzuki T, Fukazawa N, San-nohe K, Sato W, Yano O, Tsuruo T (1997) Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J Med Chem 40:2047–2052

    Article  PubMed  CAS  Google Scholar 

  33. Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917–931

    Article  PubMed  CAS  Google Scholar 

  34. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X (2002) Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 26:143–154

    Article  PubMed  CAS  Google Scholar 

  35. Tsuruo T (1988) Mechanism of multidrug resistance and implications for therapy. Jpn J Cancer Res 79:285–288

    PubMed  CAS  Google Scholar 

  36. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR (1999) c-erbB-2 (HER2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84:129–134

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Oncology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun, Saitama, 350-0495, Japan

    Toshiaki Saeki

  2. Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo, Japan

    Takashi Tsuruo

  3. Clinical Development-TH/ONC Dept., Nihon Shering K.K., Tokyo, Japan

    Wakao Sato

  4. Research and Development Division, Nippon Kayaku Co., Ltd., Tokyo, Japan

    Kiyoshiro Nishikawsa

Authors
  1. Toshiaki Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Tsuruo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wakao Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyoshiro Nishikawsa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiaki Saeki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saeki, T., Tsuruo, T., Sato, W. et al. Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 56 (Suppl 1), 84–89 (2005). https://doi.org/10.1007/s00280-005-0106-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0106-4

Keywords

Search

Navigation